PET imaging of prostate-specific membrane antigen in prostate cancer

current state of the art and future challenges

Research output: Contribution to journalArticle

Abstract

Background:Prostate-specific membrane antigen (PSMA) is a cell surface enzyme that is highly expressed in prostate cancer (PCa) and is currently being extensively explored as a promising target for molecular imaging in a variety of clinical contexts. Novel antibody and small-molecule PSMA radiotracers labeled with a variety of radionuclides for positron emission tomography (PET) imaging applications have been developed and explored in recent studies.Methods:A great deal of progress has been made in defining the clinical utility of this class of PET agents through predominantly small and retrospective clinical studies. The most compelling data to date has been in the setting of biochemically recurrent PCa, where PSMA-targeted radiotracers have been found to be superior to conventional imaging and other molecular imaging agents for the detection of locally recurrent and metastatic PCa.Results:Early data, however, suggest that initial lymph node staging before definitive therapy in high-risk primary PCa patients may be limited, although intraoperative guidance may still hold promise. Other examples of potential promising applications for PSMA PET imaging include non-invasive characterization of primary PCa, staging and treatment planning for PSMA-targeted radiotherapeutics, and guidance of focal therapy for oligometastatic disease.Conclusions:However, all of these indications and applications for PCa PSMA PET imaging are still lacking and require large, prospective, systematic clinical trials for validation. Such validation trials are needed and hopefully will be forthcoming as the fields of molecular imaging, urology, radiation oncology and medical oncology continue to define and refine the utility of PSMA-targeted PET imaging to improve the management of PCa patients.Prostate Cancer and Prostatic Diseases advance online publication, 3 May 2016; doi:10.1038/pcan.2016.13.

Original languageEnglish (US)
JournalProstate Cancer and Prostatic Diseases
DOIs
StateAccepted/In press - May 3 2016

Fingerprint

Positron-Emission Tomography
Prostatic Neoplasms
Molecular Imaging
human glutamate carboxypeptidase II
Prostatic Diseases
Radiation Oncology
Medical Oncology
Neoplasm Staging
Urology
Radioisotopes
Publications
Therapeutics
Retrospective Studies
Lymph Nodes
Clinical Trials
Antibodies
Enzymes

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research

Cite this

@article{c86a449140e54775a5e9530e82badb40,
title = "PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges",
abstract = "Background:Prostate-specific membrane antigen (PSMA) is a cell surface enzyme that is highly expressed in prostate cancer (PCa) and is currently being extensively explored as a promising target for molecular imaging in a variety of clinical contexts. Novel antibody and small-molecule PSMA radiotracers labeled with a variety of radionuclides for positron emission tomography (PET) imaging applications have been developed and explored in recent studies.Methods:A great deal of progress has been made in defining the clinical utility of this class of PET agents through predominantly small and retrospective clinical studies. The most compelling data to date has been in the setting of biochemically recurrent PCa, where PSMA-targeted radiotracers have been found to be superior to conventional imaging and other molecular imaging agents for the detection of locally recurrent and metastatic PCa.Results:Early data, however, suggest that initial lymph node staging before definitive therapy in high-risk primary PCa patients may be limited, although intraoperative guidance may still hold promise. Other examples of potential promising applications for PSMA PET imaging include non-invasive characterization of primary PCa, staging and treatment planning for PSMA-targeted radiotherapeutics, and guidance of focal therapy for oligometastatic disease.Conclusions:However, all of these indications and applications for PCa PSMA PET imaging are still lacking and require large, prospective, systematic clinical trials for validation. Such validation trials are needed and hopefully will be forthcoming as the fields of molecular imaging, urology, radiation oncology and medical oncology continue to define and refine the utility of PSMA-targeted PET imaging to improve the management of PCa patients.Prostate Cancer and Prostatic Diseases advance online publication, 3 May 2016; doi:10.1038/pcan.2016.13.",
author = "Steven Rowe and Michael Gorin and Allaf, {Mohamad E} and Kenneth Pienta and Tran, {Phuoc T} and Pomper, {Martin Gilbert} and Ross, {A. E.} and Cho, {S. Y.}",
year = "2016",
month = "5",
day = "3",
doi = "10.1038/pcan.2016.13",
language = "English (US)",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - PET imaging of prostate-specific membrane antigen in prostate cancer

T2 - current state of the art and future challenges

AU - Rowe, Steven

AU - Gorin, Michael

AU - Allaf, Mohamad E

AU - Pienta, Kenneth

AU - Tran, Phuoc T

AU - Pomper, Martin Gilbert

AU - Ross, A. E.

AU - Cho, S. Y.

PY - 2016/5/3

Y1 - 2016/5/3

N2 - Background:Prostate-specific membrane antigen (PSMA) is a cell surface enzyme that is highly expressed in prostate cancer (PCa) and is currently being extensively explored as a promising target for molecular imaging in a variety of clinical contexts. Novel antibody and small-molecule PSMA radiotracers labeled with a variety of radionuclides for positron emission tomography (PET) imaging applications have been developed and explored in recent studies.Methods:A great deal of progress has been made in defining the clinical utility of this class of PET agents through predominantly small and retrospective clinical studies. The most compelling data to date has been in the setting of biochemically recurrent PCa, where PSMA-targeted radiotracers have been found to be superior to conventional imaging and other molecular imaging agents for the detection of locally recurrent and metastatic PCa.Results:Early data, however, suggest that initial lymph node staging before definitive therapy in high-risk primary PCa patients may be limited, although intraoperative guidance may still hold promise. Other examples of potential promising applications for PSMA PET imaging include non-invasive characterization of primary PCa, staging and treatment planning for PSMA-targeted radiotherapeutics, and guidance of focal therapy for oligometastatic disease.Conclusions:However, all of these indications and applications for PCa PSMA PET imaging are still lacking and require large, prospective, systematic clinical trials for validation. Such validation trials are needed and hopefully will be forthcoming as the fields of molecular imaging, urology, radiation oncology and medical oncology continue to define and refine the utility of PSMA-targeted PET imaging to improve the management of PCa patients.Prostate Cancer and Prostatic Diseases advance online publication, 3 May 2016; doi:10.1038/pcan.2016.13.

AB - Background:Prostate-specific membrane antigen (PSMA) is a cell surface enzyme that is highly expressed in prostate cancer (PCa) and is currently being extensively explored as a promising target for molecular imaging in a variety of clinical contexts. Novel antibody and small-molecule PSMA radiotracers labeled with a variety of radionuclides for positron emission tomography (PET) imaging applications have been developed and explored in recent studies.Methods:A great deal of progress has been made in defining the clinical utility of this class of PET agents through predominantly small and retrospective clinical studies. The most compelling data to date has been in the setting of biochemically recurrent PCa, where PSMA-targeted radiotracers have been found to be superior to conventional imaging and other molecular imaging agents for the detection of locally recurrent and metastatic PCa.Results:Early data, however, suggest that initial lymph node staging before definitive therapy in high-risk primary PCa patients may be limited, although intraoperative guidance may still hold promise. Other examples of potential promising applications for PSMA PET imaging include non-invasive characterization of primary PCa, staging and treatment planning for PSMA-targeted radiotherapeutics, and guidance of focal therapy for oligometastatic disease.Conclusions:However, all of these indications and applications for PCa PSMA PET imaging are still lacking and require large, prospective, systematic clinical trials for validation. Such validation trials are needed and hopefully will be forthcoming as the fields of molecular imaging, urology, radiation oncology and medical oncology continue to define and refine the utility of PSMA-targeted PET imaging to improve the management of PCa patients.Prostate Cancer and Prostatic Diseases advance online publication, 3 May 2016; doi:10.1038/pcan.2016.13.

UR - http://www.scopus.com/inward/record.url?scp=84965055029&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965055029&partnerID=8YFLogxK

U2 - 10.1038/pcan.2016.13

DO - 10.1038/pcan.2016.13

M3 - Article

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

ER -